Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns

被引:41
作者
Emoto, C. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 4702393, Japan
关键词
CYP3A4; CYP3A5; alpha-naphthoflavone; interaction;
D O I
10.1080/00498250500489968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity. To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates. Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6 beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively. In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4. An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alpha NF) and CYP3A substrates were different for the two CYP3A enzymes. alpha NF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4. alpha NF at less than 32 mu M inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4. These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions.
引用
收藏
页码:219 / 233
页数:15
相关论文
共 31 条
[1]   Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5 [J].
Cook, CS ;
Berry, LM ;
Kim, DH ;
Burton, EG ;
Hribar, JD ;
Zhang, LM .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (12) :1344-1351
[2]   Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity [J].
Domanski, TL ;
He, YA ;
Khan, KK ;
Roussel, F ;
Wang, QM ;
Halpert, JR .
BIOCHEMISTRY, 2001, 40 (34) :10150-10160
[3]  
Emoto Chie, 2005, Drug Metab Pharmacokinet, V20, P351, DOI 10.2133/dmpk.20.351
[4]  
Emoto Chie, 2003, Drug Metab Pharmacokinet, V18, P287, DOI 10.2133/dmpk.18.287
[5]   Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: Midazolam, testosterone, and nifedipine [J].
Galetin, A ;
Clarke, SE ;
Houston, JB .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) :1108-1116
[6]  
Gibbs MA, 1999, DRUG METAB DISPOS, V27, P180
[7]   Cytochrome P-450 3A4: Regulation and role in drug metabolism [J].
Guengrich, FP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :1-17
[8]   Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4 - Role of residues 210 and 211 in flavonoid activation and substrate specificity [J].
Harlow, GR ;
Halpert, JR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (09) :5396-5402
[9]  
Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716
[10]   Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA [J].
Koch, I ;
Weil, R ;
Wolbold, R ;
Brockmöller, J ;
Hustert, E ;
Burk, O ;
Neussler, A ;
Neuhaus, P ;
Eichelbaum, M ;
Zanger, U ;
Wojnowski, L .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (10) :1108-1114